-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
Teva delivered solid Q1 2026 results with revenue of $3,982M (+2% Y/Y) and non-GAAP EPS of $0.53, beating consensus estimates of $0.46. The innovative portfolio drove growth with key brands generating $838M (+41% Y/Y), led by AUSTEDO at $578M (+41%), AJOVY at $196M (+35%), and UZEDY at $63M (+62%). This strong momentum in neuroscience products demonstrates the success of Teva's Pivot to Growth strategy, offsetting generics headwinds from lenalidomide competition. Management maintained 2026 revenue guidance of $16.4B-$16.8B but updated EPS expectations to $1.91-$2.11 due to the strategic $700M acquisition of Emalex Biosciences. The Emalex transaction adds ecopipam, a first-in-class treatment for pediatric Tourette syndrome with NDA submission expected in H2 2026. We believe this acquisition aligns with Teva's neuroscience focus and represents capital-efficient pipeline expansion; it will impact near-term margins with the expected IPR&D charge.